Study of LPX-TI641 for Atopic Dermatitis and Psoriasis
This study is testing a drug called LPX-TI641 for people with atopic dermatitis (a type of eczema) or psoriasis. We want to see how safe LPX-TI641 is and how well your body handles it compared to a placebo (a pill that looks the same but has no medicine). You would take LPX-TI641 or the placebo by mouth once a day for 28 days. The main goal is to check for any side effects and how well you tolerate the drug. We will also look at how the drug moves through your body. This study is for adults aged 18 and older.
- Study design
- This is a randomized, double-blind study, meaning participants are randomly assigned to receive either LPX-TI641 or placebo, and neither you nor your doctor will know which you are receiving. Up to 48 participants with atopic dermatitis or psoriasis will be included.
- What's involved
- You would take LPX-TI641 or placebo by mouth once a day for 28 consecutive days. You would also need to follow study protocol requirements and restrictions.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and tolerability will be evaluated for 84 days after starting the medication.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
At a glance
Conditions
Where it's being run
3 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the safety and tolerability after multiple oral doses of LPX-TI641 in participants with PsO and AD.84 days
Rate and severity of treatment-emergent adverse events, including serious adverse events.